Welcome to our dedicated page for PRESSURE BIOSCIENCES news (Ticker: PBIO), a resource for investors and traders seeking the latest updates and insights on PRESSURE BIOSCIENCES stock.
Pressure BioSciences, Inc. (PBIO) is a forefront life sciences company that focuses on the development and commercialization of an innovative platform technology known as Pressure Cycling Technology (PCT). This technology employs cycles of hydrostatic pressure, ranging from ambient to ultra-high levels (up to 35,000 psi and beyond), to precisely control biomolecular interactions, offering significant advancements in various scientific fields.
The company's core business revolves around leveraging PCT to enhance the analysis, study, and manipulation of biological samples. This technology has broad applications in areas such as protein characterization, pathogen inactivation, and the preparation of samples for genomic and proteomic studies. By utilizing PCT, researchers and scientists can achieve higher yields, improved quality, and better consistency in their biological analyses.
Recently, PBIO has made notable strides with the introduction of its new consumer products business unit, Uncle Bud’s. In January 2024, the company kicked off with a substantial $252,000 shipment of its Sunburn Soother to one of the world’s largest retailers, showcasing strong market demand and consumer interest. Additionally, VICAR Holdings LLC has committed to purchasing over 10,000 bottles of PBIO's best-in-class Nano-CBD topical spray in 2024, indicating a promising trajectory for their consumer products segment.
PBIO's relocation to a new facility has significantly increased their manufacturing space, enhanced operating efficiencies, and achieved measurable cost savings, setting the stage for unencumbered growth through multi-year expansion plans. The new facility is expected to support the company's long-term strategy and scale operations to meet growing demand.
Uncle Bud's acquisition has already yielded early synergies and measurable performance metrics within the first month, boosting PBIO's market presence and consumer engagement. This positive momentum highlights PBIO's capability to integrate and scale operations effectively.
Furthermore, Pressure BioSciences’ UltraShear platform continues to showcase its potential by enabling the development and launch of health and wellness products with groundbreaking bioavailability, fast onset, and effectiveness. This platform technology is a testament to PBIO's commitment to innovation and enhancing the quality and effectiveness of bio-molecular research and consumer applications.
Pressure BioSciences, Inc. (OTCQB:PBIO) has initiated negotiations for exclusive statewide licenses for its patented UltraShear Technology™ (UST™), aimed at transforming THC processing. Announced on April 21, 2023, the company seeks to sell five licenses to produce highly effective, water-soluble nanoemulsions of THC, which could enhance absorption rates significantly.
The licenses, valid for three years, assure exclusive production rights within designated states. Each license includes an upfront fee and the purchase of a custom-designed UltraShear instrument. PBIO projects to generate over $5 million in non-dilutive revenue from these sales, facilitating the production of UltraShear equipment for licensees. Strong interest in these licenses indicates potential market expansion, with additional Nano products in development for various major markets.
Pressure BioSciences (OTCQB:PBIO) has announced a strategic initiative to offer exclusive licenses for its patented UltraShear Technology (UST) for processing THC concentrates. This technology enables the creation of stable, bioavailable nanoemulsions, addressing the slow onset of THC edibles and the health concerns associated with smoking. The company is granting up to five 3-year exclusive licenses, with an upfront fee and cost for custom BaroShear processing equipment. Consumer testing shows that UST-processed THC can deliver effects significantly faster than traditional methods, with first effects appearing in as little as 1-10 minutes. This opportunity positions PBIO to lead innovation in the cannabis industry, bolstered by positive early data supporting the efficacy of its products.
Pressure BioSciences (PBIO) reported a strong performance in Q4 2022, with total revenue of $607,000, reflecting a 93% increase year-over-year. Instrument sales surged by 98% to $230,000, while consumable sales grew by 11%. The company has pivoted towards its UltraShear Technology (UST) platform, anticipating record revenue in Q1 2023, driven by progress in manufacturing capabilities and expanding contract negotiations in sectors like nutraceuticals and agrochemicals. However, the operating loss for FY 2022 increased by 17% to $4.9 million, with net losses per share improving only slightly from $(3.42) in 2021 to $(1.68) in 2022. The company remains confident in its revenue growth trajectory and aims for a NASDAQ or NYSE uplisting in 2023.
Pressure BioSciences, Inc. (OTCQB: PBIO) will host a teleconference on April 18, 2023, at 4:30 PM ET, to discuss its Fiscal Year 2022 financial results and provide a business update. The live presentation will be followed by a Q&A session. Key developments to be discussed include:
- Resolution of manufacturing capacity limitations, enabling larger UST processing contracts.
- Positive early data from a THC marketing study supporting rapid delivery of nano-THC products.
- Upcoming publications from leading academics demonstrating the advantages of UST nanoemulsified CBD.
- Three UST CBD contracts with a total value of $1.5 million planned for April.
- Progress in UST contract negotiations in cosmeceuticals and nutraceuticals.
- Anticipation of record Q1 2023 revenues with plans for capacity expansion and potential uplisting.
Pressure BioSciences, Inc. (PBIO) has renewed its collaboration with NutraLife Biosciences (NLBS), focusing on developing next-generation nutraceuticals using PBIO's patented UltraShear Nanoemulsification platform. This partnership aims to combine PBIO's advanced technology with NLBS's distribution network to enhance product offerings and market reach. The nutraceuticals market is projected to reach $991 billion by 2030, and this collaboration is expected to generate millions in incremental revenues for both companies starting in 2023. PBIO's technology promises improvements in bioavailability and product effectiveness, with peer-reviewed study results anticipated in the near future.
FAQ
What is the current stock price of PRESSURE BIOSCIENCES (PBIO)?
What is the market cap of PRESSURE BIOSCIENCES (PBIO)?
What is Pressure BioSciences, Inc. (PBIO)?
What is Pressure Cycling Technology (PCT)?
In which areas is PCT technology applied?
What recent achievements has PBIO made?
What is Uncle Bud’s?
How has PBIO's new facility impacted the company?
What is the UltraShear platform?
How has Uncle Bud’s performed since its acquisition?
What are some applications of PBIO’s products?
What is the significance of PBIO’s consumer products?
